Evaluation of the Association of Maternal Pertussis Vaccination With Obstetric Events and Birth Outcomes
- 12 November 2014
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 312 (18), 1897-1904
- https://doi.org/10.1001/jama.2014.14825
Abstract
Bordetella pertussis is a highly contagious human respiratory pathogen. Infants are at highest risk of severe pertussis infections. The tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) was licensed in 2005 for use in nonpregnant adolescents and adults.1 Initially, postpartum administration of Tdap to parents and other caregivers was encouraged to prevent the transmission of pertussis to newborns.1,2 However, recent outbreaks, including infant deaths,3,4 have led to changing Tdap vaccine recommendations.5This publication has 36 references indexed in Scilit:
- Receipt of pertussis vaccine during pregnancy across 7 Vaccine Safety Datalink SitesPreventive Medicine, 2014
- Inactivated Influenza Vaccine During Pregnancy and Risks for Adverse Obstetric EventsObstetrics & Gynecology, 2013
- Tetanus, Diphtheria, Acellular Pertussis Vaccine during Pregnancy: Pregnancy and Infant Health OutcomesThe Journal of Pediatrics, 2013
- Identifying pregnancy episodes, outcomes, and mother–infant pairs in the Vaccine Safety DatalinkVaccine, 2013
- California Pertussis Epidemic, 2010The Journal of Pediatrics, 2012
- Epidemic Pertussis in 2012 — The Resurgence of a Vaccine-Preventable DiseaseThe New England Journal of Medicine, 2012
- Adverse event reports after tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines in pregnant womenAmerican Journal of Obstetrics and Gynecology, 2012
- The Vaccine Safety Datalink: A Model for Monitoring Immunization SafetyPEDIATRICS, 2011
- Safety of influenza vaccination during pregnancyAmerican Journal of Obstetrics and Gynecology, 2009
- Safety of influenza vaccination during pregnancyAmerican Journal of Obstetrics and Gynecology, 2005